At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 293 enrolled
Drug / intervention
biphasic insulin aspart 30 +1 moredrug
Likely dose
metformin 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
In Brief
A Phase 4 clinical trial evaluating biphasic insulin aspart 30 and metformin for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 293 participants across 1 site.
Detailed Summary
This trial is conducted in Asia. This single arm trial aims to evaluate the blood glucose control with twice daily biphasic insulin aspart 30 in combination with metformin in Chinese subjects with type 2 diabetes inadequately controlled with once or twice daily basal insulin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedMay 2008
Primary CompletionApr 2009
TodayJul 2026
First PostedMay 1, 2008
Enrollment StartNov 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.2 years ago
Interventions
biphasic insulin aspart 30drug
Subcutaneous (under the skin) injection, twice daily
metformindrug
Tablets, 1000 - 2000 mg daily